Formulation and In vitro Evaluation of Acrivastine Controlled Release Tablets

Acrivastine has a short biological half-life of 1.9 hour and having less bioavailability which necessitates multiple daily dosing hence the present study was aimed to develop a controlled release formulation of Acrivastine to reduce the dose related side effects and to reduce the dosage regimen. The present research project aimed to develop a Control release oral formulation of anticancer drug Acrivastine, Acrivastine used for the symptomatic relief of seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion. Polymers like HPMC K4M, Carbopol 940 and HPMC K 15M were used for controlling the drug release, and the polymers are mixed in a predetermined ratio. Totally 9 formulations were prepared and evaluated for pre compression and post compression parameters, and all the results were found to be within the limits. From the drug and excipients compatability studies (FT-IR) it was confirmed that the drug and excipients used weren’t have any interactions. The in vitro dissolution studies revealed that the F9 formulation containing 150mg of HPMC K 15M controls the drug release up to 12 hours. So HPMC K 15M containing F9 formulation was considered to be suitable for the formulation of Acrivastine controlled release tablets at 150mg, and the drug release kinetics revealed that the F9 formulation shows super case transport mechanism.